National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

goserelin
A synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH) with antineoplastic activity. Goserelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors. Prolonged administration of goserelin inhibits the secretion of pituitary gonadotropin, thereby decreasing levels of testosterone (in males) and estradiol (in females). Administration of this agent in a depot formulation may result in the regression of sex hormone-sensitive tumors and a reduction in sex organ size and function. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

US brand name:Zoladex
Abbreviation:ZDX
Code name:ICI-118630
Chemical structure name:6-[O-(1,1-dimethylethyl)-D-serine]-10-deglycinamide luteinizing hormone-releasing factor (pig) 2-(aminocarbonyl)hydrazide



Previous:GM-K562 cell vaccine, GM.CD40L cell vaccine, GM2-KLH vaccine, gold sodium thiomalate, goldenrod
Next:gossypol, gp100 antigen, gp100-fowlpox vaccine, gp100:209-217(210M) peptide vaccine, gp100:280-288(288V) peptide vaccine

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov